ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements
Brooks Laboratories Ltd reported revenue from operations of ₹19.2 Cr (-18.3% YoY) and net profit of ₹67.6 Cr (+745.0% YoY) for Q2 FY27.
Brooks Laboratories will hold a board meeting on 7 November 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. The trading window is closed until 9 November 2026.
Brooks Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulatory requirements.
Brooks Laboratories approved a demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited, through a scheme of arrangement.
Brooks Laboratories informed BSE it has no additional material information to disclose regarding the recent price movement. The company attributed the share price and volume changes to purely market-driven factors.
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.
Brooks Laboratories issued an addendum to its 24th Annual General Meeting notice. The amendment modifies Resolution No. 4 regarding corporate guarantee arrangements.
Brooks Laboratories Ltd reported revenue from operations of ₹23 Cr (-9.8% YoY) and a net loss of ₹1.8 Cr for Q1 FY27.
Brooks Laboratories is informing shareholders about the availability of the Annual Report for FY 2025-26 and requesting KYC updates in compliance with regulatory requirements.
Brooks Laboratories Ltd has issued the notice for its 24th Annual General Meeting scheduled for September 3, 2026, along with the Annual Report for 2025-26.
Brooks Laboratories Limited announced a Board of Directors meeting on 13th August 2026 to approve the unaudited standalone and consolidated financial results.
Brooks Laboratories appointed Rajesh Mahajan as President - Trading effective July 17, 2026. He brings over 20 years of experience in pharmaceutical formulations and manufacturing operations.
Brooks Laboratories signed a binding MoU to sell a portion of its Brooks Steriscience stake. The deal provides Rs.106.33 Crore cash inflow and retains 32.67% equity.
Brooks Laboratories Limited filed its shareholding pattern as per Regulation 31(1)(b). The filing details holdings across promoters, institutions, and public shareholders.
Brooks Laboratories Ltd incorporated a wholly owned subsidiary, Abridge Speciality Limited. This strategic move aims to expand its pharmaceutical business operations.
Brooks Laboratories filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no new material deviations.
Brooks Laboratories appointed Mr. Prashant Rathi as CEO, effective June 1, 2026. Rathi previously served as CFO and brings 13 years of accounting experience.
Brooks Laboratories Ltd reported revenue from operations of ₹20.2 Cr (-13.3% YoY) and net profit of ₹1.5 Cr for Q4 FY26.
Brooks Laboratories reported a consolidated total income of ₹86.91 Crore for FY26. The board also appointed Mr. Prashant Rathi as CEO in addition to his CFO role.
Brooks Laboratories scheduled a board meeting on May 29, 2026, to approve audited FY2026 results. The trading window remains closed until 48 hours post-declaration.
Brooks Laboratories announced its associate entity decided to terminate the proposed composite scheme of arrangement. The transaction will not be pursued in its current form.
Brooks Laboratories Limited confirmed it does not qualify as a 'Large Corporate' for FY 2025-26 under SEBI debt-raising norms. The company reported outstanding borrowings of ₹1.19 Crore as of March 31, 2026. Its credit rating remains CARE BB; Stable / CARE A4 from CARE Ratings Limited.
Atul Ranchal, promoter of Brooks Laboratories Ltd, submitted a declaration under SEBI Takeover Regulations for FY 2025-26. The filing confirms that the promoter and promoter group made no new share encumbrances during the year, other than those already disclosed. This is a routine annual regulatory compliance disclosure.